Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.040
+0.010 (0.50%)
Sep 16, 2025, 9:55 AM EDT - Market open
Daré Bioscience Revenue
Daré Bioscience had revenue of $-21.17K in the quarter ending June 30, 2025, a decrease of -194.36%. This brings the company's revenue in the last twelve months to $-17.70K, down -100.62% year-over-year. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$-17.70K
Revenue Growth
-100.62%
P/S Ratio
-1,533.80
Revenue / Employee
n/a
Employees
23
Market Cap
26.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
Dec 31, 2022 | 10.00M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DARE News
- 4 weeks ago - Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - GlobeNewsWire
- 7 weeks ago - Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - GlobeNewsWire
- 2 months ago - UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar - GlobeNewsWire
- 2 months ago - Crude Oil Moves Lower; Daré Bioscience Shares Jump - Benzinga
- 2 months ago - Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - GlobeNewsWire
- 2 months ago - Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewsWire